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Specific Localization of b-Arrestin2 in Myenteric Plexus of
Mouse Gastrointestinal Tract
Hercules T. Maguma, Dipanjana Datta De, Sukhada Bhave, William L. Dewey, Hamid I. Akbarali*
Department of Pharmacology and Toxicology, VCU Program in Enteric Neuromuscular Sciences, Virginia Commonwealth University, Richmond, Virginia, United States of
America
Abstract
b-arrestin2 is a key molecule involved in signaling and internalization of activated G protein-coupled receptors including m-
opioid receptors (MOR). Previously we have shown that decreased expression of b-arrestin2 upon chronic morphine is
associated with the development of opioid tolerance in the gastrointestinal tract. However, the localization of b-arrestin2
within the gastrointestinal wall is not known. In this study we found that b-arrestin2 is localized in the soma of a select
group of neurons in the myenteric ganglia but not in smooth muscle. The density of b-arestin2 was significantly higher in
the ileum than the colon. We identified four variants of b-arrestin2 in the ileum, with ARRB-005 and ARRB-013 being the
most abundant. Further, the current study utilized multiple-labeling immunofluorescence to characterize the chemical
coding of neurons expressing b-arrestin2 in the murine myenteric plexus and the co-localization of MOR1 and b-arrestin2. b-
arrestin2 co-localized with choline acetyltransferase and calretinin. In contrast, b-arrestin2 neither co-localized with
substance P, nitric oxide synthase nor calbindin. Genetic deletion of b-arrestin2 did not affect cholinergic neuron activation
by nicotine in the isolated ileum (-log M EC50: wild type = 5.8 vs. b-arrestin2 knockout = 5.9). Our findings suggest specificity
in the localization of b-arrestin2 in the myenteric plexus within MOR1-expressing neurons and provide a relation for direct
intracellular crosstalk between MOR1 receptor activation and b-arrestin2 signaling in the myenteric neurons. b-arrestin2
deletion does not directly alter basal enteric cholinergic neuronal function.
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Introduction
The development of cellular tolerance following activation of G
protein-coupled receptors (GPCR) has been attributed in part to
the desensitization and internalization of the activated receptor by
the class of proteins called arrestins [1,2]. In particular, b-arrestin2
has been reported to play an integral role as a scaffolding protein
for internalization of the GPCR through clathrin-coated pits and
subsequent intracellular trafficking to subcellular compartments
(e.g. lysosomes) where GPCR degradation or dephosphorylation
occurs [3,4]. In the CNS, where b-arrestin2 has been reported to
be ubiquitously expressed [5], it has been shown that genetic
deletion of b-arrestin2 attenuates the development of tolerance to
opioid’s analgesic effect [6]. In contrast, within the colon where
morphine tolerance does not manifest, we have demonstrated that
the genetic deletion of b-arrestin2 results in the development of
tolerance to repeated morphine exposure in isolated colonic
circular muscle [7–9]. While the reason for the differences
between the effect of chronic opioids in the CNS and enteric
nervous system (ENS) is not entirely clear, we speculate that this
may be due to differential expression environment of this protein
in these tissues. We recently demonstrated that chronic opioid
exposure resulted in a time-dependent decrease in b-arrestin2
levels in the ileum [8], but do not know whether direct spatial
interaction between the endogenous opioid system and b-arrestin2
occurs in the myenteric plexus. According to Taylor and Fleming
[10], the criteria for assessing drug induced plasticity must
‘‘quantitatively account for the tolerance’’ and ‘‘occur in the very
cells upon which the opioid is acting’’. We hypothesize that b-
arrestin2 and MOR1 receptors are co-localized in the same
neuronal cells which provide the basis for intracellular crosstalk
that manifests as opioid tolerance. It is upon this basis that we
sought to investigate the chemoarchitecture of b-arrestin2
expressing neurons in the myenteric ganglia and whether or not
these neurons express MOR1 receptors. Moreover, in the NCBI
database 13 splice variants of b- arrestin have been reported.
Thus, we also elucidated the nature of the variants found in the
ileum. Various electrophysiological, neurochemical and morpho-
logical techniques have been utilized to characterize myenteric
neurons. The most widely recognized morphological classification
broadly distinguishes myenteric and submucosal neurons as Dogiel
type I or II [11] however, because of the complexity of neuronal
structures in larger mammals, more elaborate morphological
classifications have been proposed to further distinguish the
neurons [12]. An alternative classification criteria involves
neurochemical coding of the neurons based on the myriad of
neurotransmitters or calcium binding proteins expressed/stored in
the cells e.g. substance P, acetylcholine, calretinin etc. [13]. The
advantage of neurotransmitter based chemical coding is that it also
defines the function of the neuron hence paves the way for
functional assessment. The guinea pig longitudinal muscle/
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myenteric plexus (LMMP) preparation (whole mount) has been
widely used to characterize myenteric neurons in part due to its
suitability for fine dissection [11,14,15]. In this study we chose the
murine model cognizant of the difficulty involved in preparing the
mouse longitudinal muscle/myenteric plexus (LMMP) and the chal-
lenge in assessing neuronal morphological structure since the
dendrites are not elaborate [16]. In spite of these drawbacks, the
mouse LMMP model has greater utility since one can use genetic
knockouts to investigate the functional effect of a specific protein.
In the present study, we established the nature of b-arrestine2
variants found in the ileum by RT-PCR and further utilized dual
labeling immunohistochemistry to define the chemoarchitecture of
neurons expressing b-arrestin2. We used fluorescence in situ
hybridization (FISH) to identify MOR1 mRNA expression. We
report that four of the thirteen splice variants viz, ARBB-006,
ARBB-005, ARBB-013, ARBB-001 that code for b- arrestin
isoforms a and b protein are found in the ileum. Our studies (1)
clearly show the intracellular localization of b-arrestin2 and that
there is a higher density of b-arrestin2 containing neurons in the
ileum than the colon, (2) reveal extensive co-localization between
MOR1 RNA and b-arrestin2 (3) show selective expression of b-
arrestin2 in morphologically homogeneous cholinergic neurons in
the myenteric ganglia (4) exclude the expression of detectable
levels of b-arrestin2 in the other cell types including glia and
longitudinal smooth muscle cells and (5) demonstrate that the
abrogation of b-arrestin2 does not directly alter the basal
cholinergic neuronal activation.
Materials and Methods
Ethics Statement
All experimental procedures using animals were reviewed and
approved by the Institutional Animal Care and Use Committee of
Virginia Commonwealth University and were conducted in
accordance with the guidelines for the humane use of animals in
research (NIH ‘‘Public Health Service Policy on Humane Care
and Use of Laboratory Animals’’ [revised 2002]).
Drugs and Chemicals
All drugs were dissolved in distilled water to make 10 mM stock
solutions which were further diluted with distilled water to achieve
the targeted concentration. Nicotine (as hydrogen tartrate salt),
acetylcholine (as chloride salt) and colchicine were procured from
Sigma-Aldrich Co. (St. Louis, MO).
Mice
The breeding pairs for the b-arrestin2 KO mice were obtained
from Dr. Lefkowitz (Duke University, Durham, NC) and housed
within the transgenic facility at Virginia Commonwealth Univer-
sity. The animals were housed up to five per cage with access to
food and water ad libitum. The mice were moved to our
departmental animal room and kept in the facility for at least
one week to permit acclimation prior to the experiments. Every
effort was made to reduce the use of animals to the minimum
number required to achieve sufficient statistical power.
Longitudinal muscle/myenteric plexus tissue preparation
and staining
Mice were sacrificed by cervical dislocation. Segments of the
distal colon (approximately 1 cm from anus) and terminal ileum
(2 cm from ileo-cecal junction) were removed and placed in a
dissecting dish containing phosphate buffered saline (PBS). The
segments of ileum and colon were flushed of their contents and
trimmed of mesentery. Ileum or colonic segments (1 cm) were
placed in cold PBS solution and cut longitudinally along the
mesenteric border. The sheet of tissue was then pinned and
stretched on a dissecting plate containing Sylgard with the mucosal
side facing up. The tissues were incubated and fixed in 4%
paraformaldehyde for 3 hr at room temperature. Following
incubation, the paraformaldehyde was removed by rinsing the
tissue with PBS. The mucosa, submucosa and circular muscle
layers were removed using fine forceps under a dissecting
microscope and the LMMP immersed and stored in PBS
containing 0.1% sodium azide at 4uC pending immunofluores-
cence probing. For substance P staining, the excised tissue was
initially incubated in Krebs solution bubbled with 95% O2 and 5%
CO2 containing colchicine (0.01 g/100 ml) at 37uC overnight in
order to enhance the immunofluorescence [15].
Real Time PCR
Total RNA was isolated from ileum of C57/BL mouse by
TRIZOL method (Invitrogen, Life Technologies, Carlsbad, USA).
cDNa was prepared from 5 mg of the total RNA using thermo-
script reverse transcriptase (Invitrogen, Life Technologies, Carls-
bard, USA). Real time pcr (Biorad,) was performed using sybr
green chemistry (Quantifast sybr green, Qiagen,) and primers
specific for the isoforms for b- arrestin. The primers used for the
four variants are ARBB-013/ARBB-005 F: 59-CCCCAGT-
CAGCGCCCATCCA-39, ARBB-013/ARRB-006 R: 59- CAAAG-
TCCTCAAACACGATG-39, ARRB-006/ARRB-001 F: 59-AGT-
CAGCCCCCCGGGAAACAGA-39,ARRB-005/ARRB-001 R: 59-
CCTTGGAACACTGGCATAG-39. The numbers for the primers
indicate the variant it amplifies. For each variant three biological
and three technical repeats were performed. The mean Ct value
was plotted 6 SD.
Fluorescence in situ hybridization procedure (FISH)
Probe preparation. Total RNA was extracted from ileum of
C57/Bl6 mouse according to the manufacturer’s protocol by
Trizol method (Invitrogen, Life Technologies, Carlsbad, USA).
10 mg of total RNA was reverse transcribed using a Superscript
indirect cDNA labeling kit (Invitrogen, Life Technologies,
Carlsbard, USA) and OPRM-1 gene specific primers incorporat-
ing Cy5 labeled dCTP (Amersham Biosciences UK) into the
synthesized cDNA. The primer pool used to synthesize the gene
specific cDNA were designed to amplify the different splice
variants. The primer sequences used are FISH cDNA1: 59-
ACTCAAGAGTGTTCGGGTTCC-39, FISH cDNA 2:59-
ATGAACATTACGGGCAGACC-39,FISH cDNA 3:59- AGTG-
TTTTGACGGATTCGAGCAG-39,FISH cDNA 4:59-GCAGT-
CTTCATTTTGGTATAT-39. Each primer identifies one or
more splice variants of OPRM-1 gene reported in brain, since
there is little or no sequence information known about the type of
OPRM-1 variant that might be present in the mouse ileum.
In situ hybridization. Tissues were fixed with 4% parafor-
maldehyde in PBS for 20 min at room temperature followed by
incubation with proteinase K in Tris/EDTA buffer for 30 min.
The tissues were then refixed using 4% paraformaldehyde. Whole
mounts of LMMP were then pretreated with 0.5% Triton X-100
to solubilize the cell membrane and increase penetration of the
probe. Prior to the incubation with the Cy5-labelled oligonucle-
otide probe, the whole mount was incubated in a pre-hybridiza-
tion buffer (containing pre-hybrid solution, yeast tRNA, heparin
and formamide) for 1 hr. Incubation with the oligonucleotide
probe was performed overnight at 65uC. Following overnight
incubation the probe was removed using saline-sodium citrate
buffer and the sample cover-slipped for imaging.
b-Arrestin2 Expression in Myenteric Plexus
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Immunofluorescence procedures
Immunostaining procedure. Whole mounts of LMMP or
isolated cells were pretreated with 0.5% Triton X-100 to solubilize
the cell membrane and increase penetration of the primary
antibodies. Prior to primary antibody incubation, the whole mount
or isolated cells were blocked with either goat (10%) or donkey
serum (10%) for 45 minutes. Dual-labeling experiments were
performed with simultaneous incubation of primary antibodies
raised in different species targeting the proteins of interest. The
tissues were incubated in PBS containing the primary antibodies
overnight at 4uC. Following the overnight incubation, the tissues/
cells were washed with PBS and then incubated for 4 hours at
room temperature in a mixture containing the secondary
antibodies. Negative control experiments excluded the primary
antibodies and these revealed negligible faint labeling due to non-
specific binding of the secondary antibodies. Following incubation
with the respective secondary antibodies, the LMMP tissues were
mounted on slides, allowed to dry in total darkness, and then
cover-slipped pending imaging.
Image acquisition and processing. An Olympus Fluoview
F300 and a Zeiss LSM 110 laser scanning confocal microscope
were used for image acquisition and processing. In dual-labeling
experiments, a composite image targeting the two secondary
conjugates was scanned simultaneously and were separately
analyzed offline. The secondary antibody fluorophores for Alexa
488 was visualized using the 510-nm emission filter and the 605-
nm filter for Alexa 594.
Comparison of packing density of b-arrestin2 expressing
neurons in colon and ileum. Colocalization studies targeting
b-arrestin2 and the neuronal marker HuC/D were performed to
determine the packing density or percent of neurons expressing the
b-arrestin2 in the colonic and ileum LMMP preparations. For the
quantitative analysis, the anti-Hu C/D labeling was taken to
represent the total number of neurons in the ganglia and the
number of b-arrestin2 neurons was expressed as a percent of the
Hu C/D positive cells.
Neurochemical coding of b-arrestin2 expressing
neurons. To determine the chemical coding of b-arrestin2
expressing neurons, double labeling was performed using neuro-
transmitter markers (choline acetyltransferase, substance P and
nitric oxide synthase) or calcium binding proteins (calbindin or
calretinin). Colocalization between the b-arrestin2 and MOR1
receptor was determined by a modified method combining both
fluorescence in situ hybridization for MOR1 and immunohisto-
chemistry for the b-arrestin2.The primary and secondary
antibodies used are outlined in table 1. The distribution pattern
and extent of colocalization of b-arrestin2 positive neurons was
assessed qualitatively. Cells were considered to be immunopositive
if they expressed visually detectable labeling. Flouview software
was used to capture the images and Image J software was used to
analyze the distribution and determine the density of immunopo-
sitive neurons.
Functional assessment of b-arrestin2 deletion on
longitudinal muscle contraction
Following euthanization by cervical dislocation, the segments of
ileum and colon were dissected, flushed of their contents, and
trimmed of mesentery. The tissues, 1 cm in length, were
suspended vertically along the axis of the longitudinal muscle
and tied at each end with a fine thread. The thread was then
passed through platinum-ring electrodes and placed in an organ
bath containing Krebs buffer solution with one thread tied to a
force transducer and the other fixed to a tissue holder under 1 g of
passive tension. The tissues were allowed to equilibrate for 60
minutes prior to drug exposure, during which the Krebs solution
was changed every 15 minutes. Isometric contractions were
recorded by a force transducer (GR-FT03; Radnoti, Monrovia,
CA) connected to a personal computer using Acknowledge 382
software (BIOPAC Systems, Inc., Santa Barbara, CA).
Following equilibration, the tissues were exposed to non-
cumulatively increasing concentrations of nicotine (final concen-
trations in the organ bath ranging between 0.1 mM and 100 mM).
Three 4-minute washes followed by a single 10 minute wash with
drug free Krebs solution were performed between each drug
challenge to permit recovery of the tissue. In each experiment, two
LMMP preparations from each test group of animals were studied
simultaneously and the responses of the tissues from the same
animal averaged. The effect of each agonist on the amplitude of
the neurogenic contractions was calculated as percent stimulation
from the reference acetylcholine-induced (3 mM) contractions
measured at the end of the experiments. The values were used to
determine the EC50 (i.e. concentration required to produce 50% of
the maximum response) and to calculate the maximum tension
produced by nicotine. Computer assisted analysis of each
concentration-response curve using Graphpad Prism software
(SPSS Inc.) was employed to determine the EC50.
Data analysis
All data was analyzed using appropriate statistical tools using
the GraphPad Prism software (GraphPad Software Inc.). Analysis
was performed to compare the density of neurons expressing b-
arrestin2 (i.e. neurons positive for b-arrestin2/neurons positive for
Hu C/D) between the ileum and colonic tissues. Significant
differences between the test and control groups were determined
using unpaired Student’s ‘‘t’’ test. Immunofluorescence images
were analyzed qualitatively to determine colocalization between b-
arrestin2 and the targeted proteins or MOR1 RNA. For nicotine
stimulation experiments, the EC50 and the maximal isometric
tension produced were determined and compared. The percent
contraction was calculated using the mean contraction height
divided by the maximal contraction induced by acetylcholine
(3.0 mM). Contractile responses after repeated administrations of
the agonist were analyzed by repeated measures ANOVA
followed by Bonferroni post hoc test. Data are presented as mean
6 S.E.M. Values of P,0.05 were considered to be statistically
significant.
Results
Expression and density of b-arrestin2 in the LMMP
Initial studies, using the whole mount (LMMP) were performed,
to verify the specificity of the anti- b-arrestin2 primary antibody
and to determine the spatial expression of b-arrestin2 within the
myenteric ganglia from C57 BL/6 wild type and b-arrestin2
knockout mice. Fig. 1 illustrates confocal scans of the whole mount
with green immunofluorescence depicting neurons expressing b-
arrestin2 and red showing Hu C/D immunopositive neurons in
wild type mice (A, B, C). Prototypical images from wild type mice
show distinct and exclusive expression of b-arrestin2 in a select
group of neurons in the myenteric ganglia from the ileum (top
panel) and in the colon (bottom panel). The expression of b-
arrestin2 appeared to be mostly confined to the soma and little was
observed in the axonal or dendritic processes. b-arrestin2
expression was clearly absent within the nuclear compartment.
The neurons expressing b-arrestin2 were morphologically homo-
geneous with relatively larger cell bodies that are ovoid and slightly
elongated compared to the smaller and circular shaped neurons
that were only positive for the Hu C/D marker. Comparison of
b-Arrestin2 Expression in Myenteric Plexus
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the immunofluorescence signal within ganglionic neurons and the
underlying longitudinal muscle shows little or no b-arrestin2
expression in the smooth muscle layer. No distinct immunofluo-
rescence was evident for b-arrestin2 in the whole mount of b-
arrestin2 KO mice except for the non-specific background staining
(Fig. 1D, E, F). The slightly faint immunofluorescence observed in
the underlying longitudinal muscle could either be background
staining or show that this protein is not significantly expressed in
Table 1. List of antibodies for Immunohistochemistry.
Antibody (Host) Source Dilution
Primary antibodies
b-arrestin2 (rabbit) Cell signaling 1:150
Hu C/D (mouse) Abcam 1:50
Substance P (mouse) Abcam 1:1500
ChAT, acetyltransferase (goat) Millipore 1:50
Calretinin (goat) Swant 1:100
Calbindin (mouse) Swant 1:100
NOS (nitric oxide transferase) Santa Cruz. 1:50
Secondary antibodies
Alexa 488-conjugate Life Technologies 1:500
Alexa 594-conjugate Life Technologies 1:500
doi:10.1371/journal.pone.0103894.t001
Figure 1. Expression of b-arrestin2 in the myenteric plexus. b-arrestin2 is exclusively expressed in a select group of neurons in the myenteric
ganglia. Typical images from the longitudinal muscle/myenteric preparation showing immunofluorescence in neurons expressing b-arrestin2 - green
and Hu C/D - red in wild type (A, B, C) and b-arrestin2 KO (D, E, F); note absence of b-arrestin2 staining in b-arrestin2 KO. Comparison of the density of
b-arrestin2 expressing neurons in colon and ileum (bar graph on right). The density of b-arrestin2 immunopositive neurons was higher in the ileum
(10.82%) compared to the colon (4.27%), *p#0.05. Bottom panel are high magnification scans of b-arrestin2 and Hu C/D in myenteric ganglia from
mouse colon. Scale bars: Upper panels: 20 mm, lower panel 200 mm.
doi:10.1371/journal.pone.0103894.g001
b-Arrestin2 Expression in Myenteric Plexus
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the muscle. In some of the mounts, we observed faint immuno-
fluorescence in the inter-ganglionic connections, varicosities and
tertiary neuronal processes.
To compare the relative density of the neurons expressing b-
arrestin2 in the colon and ileum of C57 BL/6 wild type mice, dual
labeling was performed using antibodies targeting b-arrestin2 and
Figure 2. Expression of b-arrestin2 variants in Ileum. Real time PCR analysis depicts presence of four b- arrestin2 variants in ileum and colon.
The relative expression of each variant was examined in the ileum and colon (n = 3) with 18s rRna was used as an endogenous control.
doi:10.1371/journal.pone.0103894.g002
Figure 3. Representative images of LMMP whole mounts comparing expression of NOS, and substance P in b-arrestin2
immunopositive neurons. A: b-arrestin2-immunopositive neurons (green). B: NOS -immunopositive neurons (red). C: merged image depicting of
b-arrestin2 and NOS fluorescence. D: b-arrestin2-immunopositive neurons (green). E: Substance P-immunopositive neurons (red). F: merged image
depicting colocalization of b-arrestin2 and Substance P. Scale bars: Upper panel 20 mm: bottom panel 50 mm.
doi:10.1371/journal.pone.0103894.g003
b-Arrestin2 Expression in Myenteric Plexus
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HuC/D, a marker used to represent the total number of neurons
in the ganglia. Bar graph in Fig. 1 shows a comparison of the
density of b-arrestin2 expressing neurons in colon versus the ileum.
Interestingly, the density of b-arrestin2 immunopositive neurons
was significantly higher in the ileum (10.82%61.4) compared to
the colon (4.27%60.14). The significance of this variance is not
yet apparent and will be investigated in additional studies.
b- arrestin 2 is known to have 13 splice variants of which six
produce functional proteins. We have previously reported that b-
arrestin levels in the ileum decrease in response to chronic
morphine exposure that results in the induction of tolerance. Thus,
it is important to know which transcripts are expressed in the
ileum. However, there are no previous reports to elucidate the
nature of the transcripts that are encoded in the ileum and colon.
A preliminary mi-SEQ analysis (data not shown) identified the
presence of four of the thirteen variants. We confirmed that
ARBB2-005, ARBB2-006, ARBB2-013, and ARBB2-001 tran-
scripts are found in the ileum and in the colon (figure 2). These
transcripts are reported to encode for proteins that are similar to
isoforms a and b of b- arrestin2. The expression of each of the
transcripts was greater in ileum compared to the colon.
Neurochemical coding of neurons expressing aˆ-arrestin2
Neurotransmitter markers. Previous studies focusing on
the myenteric ganglia have shown that the majority of excitatory
neurons are associated with acetylcholine and substance P whereas
inhibitory neurons tend to express nitric oxide (NO), vasoactive
intestinal peptide (VIP), norepinephrine, adenosine triphosphate
(ATP) and pituitary adenylate cyclase-activating polypeptide
(PACAP) (McConalogue and Furness, 1994). To determine the
neurotransmitter coding of neurons expressing b-arrestin2 we
utilized markers targeting ChAT, nitric oxide synthase (NOS) and
substance P which are markers for cholinergic, nitrergic and
tachykinergic neurons respectively. Representative images from
whole mounts of the mouse LMMP showing the neurotransmitter
markers in the myenteric plexus are shown in Fig 3 and 4. The
green immunofluorescence (Fig 3 A and D) indicating b-arrestin2-
expressing neurons is consistent with previous findings with respect
to morphological structure and distribution. The red immunoflu-
orescence in Fig 3B depicts widespread NOS expression in the
myenteric ganglia, however, no co-localization is observed with b-
arrestin2 suggesting that b-arrestin2 is not expressed in inhibitory
nitrergic neurons. Substance P is a critical moiety involved in
excitatory signaling in the enteric nervous system and has been
reported to be co-released with acetylcholine. We therefore
assessed whether b-arrestin2 is also co-localized with substance
P. To enhance substance P immunofluorescence signal within the
soma, tissues were incubated in colchicine for 4 hours prior to
fixing with paraformaldehyde. Following colchicine treatment,
substance P pattern of distribution was not only visible in cell
bodies but also in varicosities and tertiary neuronal fibers (Fig. 3E).
The merged images depicting b-arrestin2 and substance P
expression (Fig. 3F) clearly show that the two proteins are
expressed in different neurons since no co-localization was
observed. The red immunofluorescence in Fig 4 shows ChAT
expressing neurons; upon merging with b-arrestin2 expression, it is
evident that robust expression of b-arrestin2 was observed in
cholinergic neurons as depicted by the cell bodies in merged
image. The majority of b-arrestin positive cell bodies co-localized
with ChAT which accounted for about 50% of all ChAT positive
neurons in 6 separate ganglia (Fig 4).
We investigated the expression of MOR1 in neurons. As
suggested previously, the antibody to MOR1 shows significant
non-specificity [17], we therefore examined expression of MOR1
Figure 4. b-arrestin2-immunopositive neurons (green) and ChAT -immunopositive neurons (red), merged image depicting co-
localization of b-arrestin2 and ChAT (yellow). Bottom bar graph are total b-arrestin2 positive and ChAT positive neurons from 6 ganglia. Scale
bars: 20 mm.
doi:10.1371/journal.pone.0103894.g004
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Figure 5. Image of myenteric ganglia expression of MOR1 mRNA in b-arrestin2 immunopositive neurons. b-arrestin2-immunopositive
neurons (grey) with punctate mRNA for MOR1 (red) determined my mRNA-FISH. A) High magnification of merged image showing expression of MOR1
(red) within cell bodies labeled with b-arrestin2 (grey). B) grey scale image of b-arrestin2, C) fluorescent Cy5 labeled MOR1 – mRNA. Arrows are non-
specific staining of cells outside the ganglia. D) Cy5 labelling of MOR1 mRNA in isolated ileum smooth muscle cell. Nuclear stain (blue). Middle panel
indicates the absence of Cy5 fluorescent in smooth muscle. Bright field image of smooth muscle cell on the right panel. Scale bar: 20 mm.
doi:10.1371/journal.pone.0103894.g005
Figure 6. Representative images of LMMP whole mounts comparing expression of calbindin and calretinin in b-arrestin2
immunopositive neurons. A: b-arrestin2-immunopositive neurons (green). B: calbindin-immunopositive neurons (red). C: merged image
depicting expression of b-arrestin2 and calbindin. D: b-arrestin2-immunopositive neurons (green). E: calretinin -immunopositive neurons (red). F:
merged image depicting colocalization of b-arrestin2 and calretinin (yellow). Scale bars: Upper panel: 50 mm, bottom panel: 20 mm.
doi:10.1371/journal.pone.0103894.g006
b-Arrestin2 Expression in Myenteric Plexus
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transcript by mRNA-FISH. Based on Taylor and Fleming’s
criteria for assessing drug induced plasticity the changes observed
must ‘‘quantitatively account for the tolerance’’ and ‘‘occur in the
very cells upon which the opioid is acting’’ [10], we assessed
whether b-arrestin2 was indeed co-localized with the MOR1
receptor. Fig. 5 illustrates confocal scan of the whole mount with
gray image depicting b-arrestin2 expression in cell bodies within
the myenteric ganglia and red punctate fluorescence of the mRNA
for MOR1 (Fig. 5). Consistent with mRNA expression, the MOR1
receptor expression, represented by defined punctate staining, was
clearly distinct in the cytoplasmic space and none in the nuclear
compartment. Control experiments using underlying longitudinal
muscle that is devoid of the myenteric ganglia show little or no
MOR1 mRNA expression hence confirming validity of the
preparation and specificity of the Cy5 labeled oligonucleotide
probe. Furthermore, expression of mRNA-FISH for MOR1 was
also not evident in isolated smooth muscle cells (fig 5D). Intense
non-specific staining was observed in red blood cells (arrows).
Co-localization with calcium-binding proteins. For these
experiments, we utilized two calcium binding protein markers;
calbindin, a conserved protein usually used to mark sensory
neurons [15], and calretinin which has been widely used as a
marker for motor neurons in guinea pigs [18]. Representative
images from whole mounts of the mouse LMMP showing
calbindin and calretinin immunopositive neurons in the myenteric
plexus are provided in Fig 6. The green immunofluorescence
(Fig 6A, D) indicates b-arrestin2-expressing neurons while the red
immunofluorescence in Fig 6B depicts calbindin expressing
neurons and the red in Fig 6E depicts calretinin expressing
neurons. As shown in the merged images, b-arrestin2 is clearly not
expressed in calbindin-positive neurons. Calbindin expression was
observed in the soma and axonal projections. The multiple
dendritic projections are consistent with the observations reported
in guinea pigs and correlate with Dogiel type II neuronal structure
of intrinsic primary sensory afferent neurons [18]. In addition, the
varicosities seem to reside predominately in the periphery of the
myenteric ganglia whereas the b-arrestin2 expressing cell bodies
are congregated in the central part of the ganglia. In contrast,
robust expression of b-arrestin2 was observed in calretinin
immunopositive neuron as depicted by the yellow cell bodies
(Fig 6F). Table 2 is a summary of the results of neurochemical
coding for a proteins assessed. In summary, b–arrestin 2 was found
in calretinin expressing neurons and not in Calbindin expressing
neurons.
Effect of b-arrestin2 deletion on the sensitivity to nicotine
One of the issues associated with using genetic knockouts is the
possibility of an aberrant change in normal physiological function.
Based on the previously outlined results that show clear expression
of b-arrestin2 in the myenteric ganglionic cholinergic neurons, we
set out to determine whether genetic deletion of this protein would
alter basal physiological cholinergic transmission in the myenteric
ganglia. To this end, we used the longitudinal muscle preparation
from C57 BL/6 wild type versus the paired b-arrestin2 knockout
mice to assess possible changes in potency and efficacy of nicotine
which targets the neuronal nicotinic receptors exclusively
expressed in the myenteric plexus. As illustrated in Fig. 7, genetic
deletion of b-arrestin2 did not change the functional response of
the ileum longitudinal muscle to nicotine since the potency was
similar among the two groups (-log EC50: C57BL/6 wild
type = 5.76 vs. b-arrestin2 knockout = 5.90). A marginal decrease
in the maximal efficacy of nicotine was observed (Fig. 8) but it was
not statistically significant (C57BL/6 wild type= 0.67 g60.18 vs.
b-arrestin2 knockout = 0.44 g60.07; P= 0.26).
Discussion
Previous studies from our lab strongly suggest a direct
interaction between MOR activation and b-arrestin2 since
downregulation of b-arrestin2 is associated with the development
of tolerance to opioids in the intestinal tract [8] [7]. b-arrestin2, is
a key molecule involved in desensitization of activated G protein-
coupled receptors. We therefore examined possible colocalization
of b-arrestin2 with the MOR1 receptor. In the present study, we
sought determine the relative expression of b–arrrestin2 in various
portions of the gastrointestinal tract as well as intracellularly in
these tissues. Further, we determined the nature of the b- arrestin2
isoforms expressed in ileum and also the type of enteric cells
expressing b-arrestin2. We investigated the impact of b-arrestin2
abrogation on basal cholinergic function. A number of studies
have focused on studying the spatial expression of b-arrestin2 in
the CNS, but few have investigated the specific localization of b-
arrestin2 in the enteric nervous system.
b-arrestin2 is not only required for desensitization of the
activated GPCR, but also serves as a signaling moiety through
Janus kinase (JNK), mitogen activated kinase (MAK) and Src
kinase pathways [19-21]. Because of its integral function in cell
plasticity it is critical to assess chemoarchitecture of neurons
expressing b-arrestin2 in the myenteric ganglia. To the best of our
knowledge, this is the first study undertaken to determine the
nature and spatial expression of b-arrestin2 within the myenteric
ganglia. We report the presence of ARBB2-005, ARBB2-006,
ARBB2-013 and ARBB2-001 transcripts in the ileum. These
transcripts encoded for protein that are similar to the reported b-
arrestin2 isoform a and isoform b proteins. The distribution of
individual variants show that ARBB2-005 is the most abundant
transcript followed by ARRB2-013. This study for the first time
unravels the identity of the b- arrestin variants in ileum and colon.
Understanding the function of these proteins in both the ileum and
brain as opposed to the colon might well be useful information in
studying the differences in morphine tolerance in these tissues. The
primary findings of this study describe the presence of b-arrestin2
in neuronal cell bodies of both tissues, but do not distinguish the
role of this protein in opioid tolerance. Further studies to examine
the changes in expression levels will be required to elucidate the
functional role in tolerance development.
Our studies also demonstrate selective expression of b-arrestin2
in the enteric nervous system in contrast to the ubiquitous
expression of this protein in the CNS [5]. The b-arrestin2
expressing neurons are remarkably distinct. They are compara-
tively larger, more oval-shaped and can be clearly distinguished
from the smaller and circular NOS expressing neurons [22]. The
colocalization of b-arrestin2 with ChAT and calretinin suggests
that these neurons are cholinergic and may likely be motor
Table 2. Chemoarchitecture of b-arrestin2 expressing
myenteric neurons.
Type of neuron Marker Result
Nitrergic Nitric oxide synthase -
Calbindin -
Cholinergic Choline acetyltransferase (ChAT) +
Calretinin +
Tachykinergic Substance P -
doi:10.1371/journal.pone.0103894.t002
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Figure 7. Mean concentration-response curves for nicotine in longitudinal ileum preparation obtained from WT or b-arrestin2 KO
mice. A slight but insignificant change to the sensitivity to nicotine was observed in the b-arrestin2 knockout mice (A). B) representative isometric
tension recording tracing of the longitudinal ileum preparation from C57BL/6 WT mice showing the non-cumulative dose response effect of repeated
exposure with nicotine. Statistically significant differences (p#0.05) are identified by *.
doi:10.1371/journal.pone.0103894.g007
b-Arrestin2 Expression in Myenteric Plexus
PLOS ONE | www.plosone.org 9 August 2014 | Volume 9 | Issue 8 | e103894
neurons. However, it should be noted that distinction of motor and
sensory neurons based on the calcium-binding proteins has been
defined in the guinea-pig but may differ in mice. Since a fraction
of the b-arrestin2 positive neurons did not co-express ChAT,
suggests that the b-arrestin2 expressing neurons are neurochem-
ically heterogeneous. Other possible neuromarkers that could be
utilized to further characterize the neurons include serotonin, VIP
or PACAP.
The density of neurons expressing b-arrestin2 is significantly
higher in the ileum compared to the colon. While the significance
for this physiological difference is not apparent, it could have a
bearing on the differences in GPCR plasticity and the level of
morphine tolerance seen in the two segments of the gastrointes-
tinal tract [8]. The fact that we discovered selective expression of
b-arrestin2 in enteric neurons challenges the notion that this
protein is ubiquitously expressed in cells that express GPCRs.
Several GPCRs including the M2 muscarinic receptors are
expressed in enteric smooth muscle cells. In the present studies
we show that b-arrestin2 is not found in these cells suggesting that
other b-arrestin2-independent pathways may dominate GPCR
desensitization.
In previous studies, we have shown that the development of
tolerance to morphine in the isolated ileum is associated with a
time dependent reduction in the b-arrestin2 levels [8]. However,
in those studies, western immunoblotting in digested isolated
myenteric neurons or LMMP tissue was used to assess protein
expression. Unfortunately, this method neither reveals the spatial
location of the cells expressing b-arrestin2, morphological
structure of the cells nor possible neuronal projections. More
importantly, no direct link could be established between cells being
activated by morphine and those where b-arrestin2 is expressed.
The current study reports that the majority of neurons expressing
b-arrestin2 also expressed MOR1 suggesting a possible direct
intracellular link between MOR1 activation and b-arrestin2
downregulation associated with opioid tolerance in the ENS. In
addition, the selective expression of MOR1 in neurons confirms
our previous functional findings and support the school of thought
that MOR1 receptors are selectively expressed in the neurons and
not in the smooth muscle. Our discovery that b-arrestin2 is
exclusively expressed in neuronal cells suggests that the opioid
tolerance observed following b-arrestin2 deletion is likely due to
plasticity within the myenteric plexus [7]. Based on the current
findings showing co-localization between MOR1 and b-arrestin2,
and on previously published data showing morphine induced
downregulation of b-arrestin2 [5,8], we postulate that morphine
tolerance triggered by sustained activation of MOR1 receptors is,
at least partially, imparted in b-arrestin2 expressing neurons and
potentially represents an important therapeutic target.
Though most studies have utilized the guinea pig LMMP model
to characterize myenteric neuron identity, one major advantage of
using the murine model is the availability of genetic knockouts. In
the current study, we were able to classify the neurons using five
specific markers. However, we had difficulty characterizing the
neurons morphologically according to the well-established Dogiel
and Brehmer classifications which distinguish neurons based on
the number and length of axonal and dendritic projections [12].
Our experiments using the neurofilament marker (results not
shown) were especially challenging and complicated by the fact
that axonal and dendritic projections in the murine LMMP are
not as elaborate as other species e.g. guinea pig hence makes it
difficult to distinguish the subtypes of mono-axonal neurons [16].
One drawback of utilizing genetic knockout models is the
possible aberration of a normal physiological response as has been
frequently observed in several models. The current study clearly
shows that the abrogation of b-arrestin2 did not alter the efficacy
and potency of ganglionic cholinergic innervation in the isolated
longitudinal preparation. This finding supports our previous
observation in the isolated circular muscle [7] and suggests that
b-arrestin2 is not involved in the acute effects of cholinergic
neuronal activation. Alternatively, since the cholinergic system is
so expansive in the myenteric ganglia, the organ bath assay may
not have been ideal to discern the subtle changes imparted by b-
arrestin2 deletion in neurons since these constitute 10% in the
ileum and only 4% in the colon. We are in the process of
Figure 8. Shows a bar graph comparing the maximal tension values attained by nicotine (A) or acetylcholine (B) stimulation in the
longitudinal ileum preparation from WT or b-arrestin2 KO mice. No significant increase in maximal efficacy to nicotine or acetylcholine.
Statistically significant differences (p#0.05) are identified by *.
doi:10.1371/journal.pone.0103894.g008
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investigating the effect of chronic opioid exposure on the potency
of agents targeting the nicotinic ganglionic receptors.
In summary, the data presented in this paper show that b-
arrestin2 is expressed in myenteric neurons and not other cell
types like smooth muscles or glia. In addition, MOR1 receptors
appear to be co-expressed in a b-arrestin2 positive myenteric
neurons that are likely cholinergic motor neurons. These neurons
may be directly involved with the tolerance observed following
chronic morphine exposure since it is associated with a time
dependent reduction in b-arrestin2 levels within the myenteric
plexus. The fact that b-arrestin2 is expressed in cholinergic
neurons suggests a complex interplay between intraneuronal and
possibly interneuronal interaction that may reflect the specific
adaptive processes involved in the development of tolerance to
opioids. The greater density of neurons expressing b-arrestin2 in
the ileum compared to the colon might be a contributing factor to
the expression of tolerance to opioids in the ileum and not the
colon.
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